Free tool
FAERS Monitor: Cytalux
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214907 or its brand name (Cytalux, Pafolacianine Sodium). Reports on generic versions are filed under their own applications.
Reports
63
Serious
13
21% of reports
Hospitalization
8
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea35
- vomiting20
- pruritus7
- dyspnoea6
- chest discomfort5
- drug effect less than expected4
- flushing4
- wheezing4
- false positive investigation result3
- hyperhidrosis3
- abdominal pain2
- chest pain2
- death2
- dizziness2
- heart rate increased2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 2 |
| 2024 | 24 |
| 2025 | 19 |
| 2026 | 18 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,096 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| false positive investigation resultSignal | 3 | 995.6 | 329.4 | 2,063 |
| drug effect less than expectedSignal | 4 | 90.1 | 34.9 | 269 |
| wheezingSignal | 4 | 22.5 | 8.7 | 62 |
| chest discomfortSignal | 5 | 16.3 | 7.0 | 58 |
| nauseaSignal | 35 | 14.8 | 11.8 | 452 |
| vomitingSignal | 20 | 14.2 | 9.9 | 238 |
| flushingSignal | 4 | 13.1 | 5.1 | 34 |
| hyperhidrosisSignal | 3 | 7.8 | 2.6 | 12 |
| heart rate increased | 2 | 6.7 | 1.7 | 5 |
| pruritusSignal | 7 | 6.1 | 3.0 | 25 |
| chest pain | 2 | 3.6 | 0.9 | 2 |
| dyspnoeaSignal | 6 | 3.5 | 1.7 | 9 |
| abdominal pain | 2 | 2.9 | 0.7 | 1 |
| dizziness | 2 | 1.3 | 0.3 | 0 |
| death | 2 | 0.8 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.